Press Releases

Date Title and Summary View
Toggle Summary Revance to Participate in the Credit Suisse Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 7, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare
View HTML
Toggle Summary Revance Releases Third Quarter 2018 Results
- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation
View HTML
Toggle Summary Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
-Conference Call Scheduled for Thursday, November 1, 2018 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)--Oct. 18, 2018-- Revance Therapeutics, Inc.  (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
NEWARK, Calif. --(BUSINESS WIRE)--Oct. 11, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C.
View HTML
Toggle Summary Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Sep. 24, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare
View HTML
Toggle Summary Revance Receives Great Place to Work Certification
NEWARK, Calif. --(BUSINESS WIRE)--Sep. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent
View HTML
Toggle Summary Revance Releases Second Quarter 2018 Results
NEWARK, Calif. --(BUSINESS WIRE)--Aug. 2, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018 .
View HTML
Toggle Summary Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
-Conference Call Scheduled for Thursday, August 2, 2018 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)--Jul. 19, 2018-- Revance Therapeutics , Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
- RT002 Injectable has potential to be first long-acting neuromodulator for treatment of a debilitating involuntary muscle movement disorder - NEWARK, Calif. --(BUSINESS WIRE)--Jun. 21, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in
View HTML
Toggle Summary Revance to Participate in the JMP Securities Life Sciences Conference 2018
NEWARK, Calif. --(BUSINESS WIRE)--Jun. 14, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools